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Episodes of acute adenolymphangitis (ADL) are often the first clinical sign of lymphatic filari-
asis (LF). They are often accompanied by swelling of the affected limb, inflammation, fever,
and general malaise and lead to the progression of lymphedema. Although ADL episodes
have been studied for a century or more, questions still remain as to their etiology. We quan-
tified antibody levels to pathogens that potentially contribute to ADL episodes during and
after an episode among lymphedema patients in Léogâne, Haiti. We estimated the propor-
tion of ADL episodes hypothesized to be attributed to specific pathogens.
Methods
Wemeasured antibody levels to specific pathogens during and following an ADL episode
among 41 lymphedema patients enrolled in a cohort study in Léogâne, Haiti. We calculated
the absolute and relative changes in antibody levels between the ADL and convalescent
time points. We calculated the proportion of episodes that demonstrated a two-fold increase
in antibody level for several bacterial, fungal, and filarial pathogens.
Results
Our results showed the greatest proportion of two-fold changes in antibody levels for the
carbohydrate antigen Streptococcus group A, followed by IgG2 responses to a soluble filar-
ial antigen (BpG2), Streptococcal Pyrogenic Exotoxin B, and an antigen for the fungal path-
ogen Candida. When comparing the median antibody level during the ADL episode to the
median antibody level at the convalescent time point, only the antigens for Pseudomonas
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Conclusion
Although our results are limited by the lack of a control group and few antibody responses,
they provide some evidence for infection with Streptococcus A as a potential contributing
factor to ADL episodes. Our results add to the current evidence and illustrate the importance
of determining the causal role of bacterial and fungal pathogens and immunological antifilar-
ial response in ADL episodes.
Introduction
Lymphatic filariasis (LF) is a neglected tropical disease affecting 68 million people throughout
the world [1]. The disease is caused by 3 different species of parasitic nematode worms,
Wuchereria bancrofti, Brugia malayi, and Brugia timori [2], which are spread by several genera
of mosquitoes. These thread-like worms reside in the lymphatic vessels of humans, causing
lymphatic damage.
While often characterized by chronic lymphedema and ultimately elephantiasis of the
limbs, the first clinical sign of lower limb LF disease is typically an episode of acute adenolym-
phangitis (ADL). ADL is characterized by a plaque-like area of relatively diffuse cutaneous
inflammation with or without ascending lymphangitis or satellite adenitis [3]. ADL episodes
are accompanied by swelling, inflammation, high fever, general malaise and chills. The epi-
sodes are a recurrent clinical aspect of LF lasting 3–15 days each and may occur several times
each year [4]. ADL episodes are often accompanied or followed by distal edema of the affected
leg [3]. Clinical evidence has shown that ADL episodes can lead to the progression of chronic
lymphedema [5–8]. Furthermore, ADL episodes have been shown to have a substantial eco-
nomic impact through the loss of productive work days and the direct cost of treatment [9–11].
Despite extensive research, the etiology of ADL episodes is yet to be fully understood.
Although there has been evidence for bacterial pathogens such as Streptococcus A and Staphylo-
coccus as the causal agent in ADL episodes [12–16], other studies have attributed them to the
host’s inflammatory/immune response to adult filarial worms in the lymphatic system or
microfilariae in the blood [17,18]. Other studies suggest that filarial larvae likely contribute to
observed ADL episodes [19] or have found associations between filarial intensity and ADL
incidence [20]. Additionally, recent work has focused on the role of theWolbachia endosymbi-
ont in ADL episodes [21]. The role of fungal infections in predisposing to ADL episodes has
also been explored [22,23]. Fungi can cause entry lesions, often between the toes and within
deep skin folds[24], which serve as points of entry for bacteria.
Understanding the etiology and immunology of ADL episodes is important because they
contribute to the progression of chronic LF—a major cause of disability worldwide. Our objec-
tive was to understand how antibody response to different antigens changes over the course of
an ADL episode in order to inform models of ADL episode causality. To do this, we quantified
antibody levels to pathogens that potentially contribute to ADL episodes during and after an
episode among lymphedema patients in Léogâne, Haiti.
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Methods
Study population
Between June 1995 and December 1997, lymphedema patients were enrolled in a study to test
the feasibility and effectiveness of a basic lymphedema management program [25]. Patients
were recruited at the outpatient clinic of Ste. Croix Hospital in Léogâne, Haiti, which is
endemic forWuchereria bancrofti. Patients were included if they had lymphedema of the leg,
agreed to return to the clinic for follow-up evaluations, and did not have an obvious cause of
edema such as a tumor. Data were collected on demographics, number and history of ADL epi-
sodes, and leg volume. Patients’ lymphedema was classified into stages using the 7-stage system
of Dreyer and colleagues [26], and stages 4–7 were collapsed into a single fourth-stage category
[25]. Of 302 patients who first received lymphedema care at the clinic during the enrollment
period, 230 were enrolled. Of these, 175 returned to the clinic for at least 5 routine follow-up
visits over a period of 6 months and were included in the original cohort. All patients contin-
ued through the end of the study until December 1998.
A subset of 41 patients of the original 175 patients was used for this analysis. In addition to
the demographic, ADL, and leg volume information, serum samples were collected from these
patients. During an ADL episode, patients were instructed to report to the clinic where a serum
sample was taken. They were then instructed to return to the clinic after the ADL episode had
ended for collection of a convalescent serum sample. Attempts were made by the investigators
to obtain serum samples from all 175 patients enrolled in the original cohort, but not all
patients were able to get to the hospital during an ADL episode as they may have been disabled
and others did not consent to have their blood drawn. Thirty three of the 41 patients had
serum samples taken during and following one ADL episode comprising 33 paired samples.
Eight patients had serum samples during and following multiple ADL episodes: 3 of which had
serum drawn during and after 3 episodes comprising 9 paired samples and 5 had serum drawn
during and after 2 episodes comprising 10 paired samples. Overall there were a total of 52
paired samples and 104 observations. The current analyses were conducted post-hoc from
2013–2014.
Ethics statement
The study was approved by the Ethics Committee of Ste. Croix Hospital and by the Institu-
tional Review Board of the Centers for Disease Control and Prevention. To be eligible for par-
ticipation, patients were required to provide written informed consent.
Pathogen specific antigens
The samples collected from 1995–1998 were stored at -20°C at the CDC Laboratories in the
Division of Parasitic Diseases and Malaria until testing was completed in 2000. We measured
the antibody level for a variety of filarial, bacterial, and fungal pathogens hypothesized to be
associated with ADL episodes. To test for filarial antibodies we used Brugia pahangi antigens
that were extracted from adult worms as previously described [22]. These assays measure anti-
body responses to filarial antigens following Brugia andWuchereria infections. Isotype-specific
responses were measured with isotype-specific monoclonal antibodies. An IgG1 response to
Brugia (BpG1) is considered to be a measure of filarial exposure [27], whereas BpG4 is a mea-
sure of filarial IgG4 antibody which is associated with active filarial infection [28] and is higher
among microfilaremic patients (those with microfilariae circulating in the blood) as well as
antigen-positive persons [29,30]. We also measured filarial IgG2 and IgG3 antibodies through
the BpG2 and BpG3 antigen tests.
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IgG antibodies to the fungal pathogens Candida and Trichophyton were measured using
crude extracts from culture organisms. We measured IgG antibody to the bacterial pathogen
Streptococcus A with several different antigens: the virulence factors Streptococcal Pyrogenic
Exotoxin A (SPEA) and Streptococcal Pyrogenic Exotoxin B (SPEB), the hemolytic exotoxin
Streptolysin O (SLO), and the carbohydrate antigen Streptococcus group A (StrepA). In addi-
tion to the streptococcal bacterial pathogens, we measured IgG responses to Pseudomonas
using an exotoxin antigen and Staphylococcus using Staphylococcus enterotoxin B (SEB).
Serologic assays
The Og4C3 ELISA assay [31]to detect circulatingWuchereria bancrofti antigen was used to
determine which lymphedema patients were currently infected with the parasite. Assays to
detect antibody response to adult filarial antigen were performed using biotinylated monoclo-
nated antibodies (Zymed Laboratories, San Francisco, CA) specific for IgG1, IgG2, IgG3, and
IgG4. Assays for antibody response to Streptococcus group A (Lee Laboratories, Grayson, GA),
Streptolysin O, Pseudomonas exotoxin (List Biological Laboratories), Staphylococcus entero-
toxin B (Sigma Chemical Co., St. Louis, MO), Candida, and Trichophyton were done using bio-
tinylated monoclonal antibodies for total IgG. All antibodies were standardized against a high-
titered serum sample included in each assay and arbitrarily assigned an antibody level of
10,000 units per ml. Antibody levels were then transformed into arbitrary units (AU). Plasma
levels for all antigens were assayed in triplicate at a final dilution of 1:50. Acute and conva-
lescent samples from a given patient were run on the same plate.
Sufficient component cause models
In exploring potential filarial, bacterial, or fungal pathogens associated with ADL episodes, we
conceptualized them using sufficient component cause models (SCCM) [32]. We assume that
infection with these pathogens leads to an antibody response. These infections may or may not
interact with a number of measureable factors such as age and gender and unknown factors
such as genetics and the surrounding environment, ultimately leading to the ADL episode. In
this framework, each risk factor for the outcome of interest is defined as a component cause or
predisposing factor of the outcome of interest. Each component cause contributes to one or
more sufficient causes, which contain the minimal set of conditions that result in the outcome
[33–35]. An outcome may have a single or multiple sufficient causes.
Fig 1 displays potential SCCMs for ADL episodes. Model 1 states that at minimum, the pres-
ence of a bacterial infection such as Streptococcus A along with unknown factors U1 is sufficient
to cause an episode of ADL. Model 2 states that at minimum, a reaction to filarial worm infec-
tion in combination with unknown factors U2 must be present for ADL episode to occur.
Model 3 states that at minimum, the presence of a fungal infection such as Trichyophtyon in
combination with unknown factors U3 is sufficient to cause an episode of ADL. Model 4
involves a biological interaction of infection with both a bacterial and fungal pathogen. The
fungal pathogen causes a lesion on the skin of the affected limb, which then provides an entry
point for bacteria and the subsequent response to infection in the form of an ADL episode. The
unknown factors stated in these SCCMs may comprise a multitude of environmental, genetic,
and immunologic factors. The examples of sufficient component causes displayed in Fig 1 rep-
resent only a few of the many potential sufficient cause models for ADL episodes.
Antibody change assumptions
If infection by a particular pathogen immediately prior to an ADL episode contributes to the
etiology of the episode, we expect the antibody levels to increase from the ADL to the
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convalescent time point [12,16,36]. We assumed that in the context of lymphedema patients
with recurrent ADL episodes and bacterial/fungal infections, if the antibody level of a pathogen
is found to increase two-fold from the ADL to the convalescent time point, it is considered a
component cause of ADL.
Statistical analysis
For each antigen, we calculated an absolute change and percent change from the ADL to con-
valescent time point:
Absolute Change ¼ Antibody LevelConvalescent  Antibody LevelADL
Percent Change ¼ ½ðAntibody LevelConvalescent  Antibody LevelADLÞ=ðAntibody LevelADLÞ X100
Since the distribution of antibody change in this population was not normal, we reported
median values for the absolute antibody values, absolute change, and percent change along
with the standard deviation and inter-quartile range (IQR). We conducted a Wilcoxon signed
rank test to detect a difference between ADL and convalescent median antibody levels.
For each antigen we calculated the proportion of antibody response as the number of cases
showing an antibody change at the two-fold level divided by the total number of ADL episodes
in the sample. The denominator for the proportion is 52 ADL episodes.
Proportion of Two Fold Antibody Response ¼ # of episodes showing two fold change
52 ADL episodes
Results
The majority of the lymphedema patients were female (83%) with a median age of 34 years
(Table 1). Most patients presented with stage 2 or 3 lymphedema. Only 1 of the 41 patients
tested positive for circulating filarial antigen (CFA) at either the ADL or the convalescent time
point. Prior to cohort enrollment, the yearly ADL rate among lymphedema patients was 2.7
per person year. During the entire lymphedema cohort enrollment, 1995–1998, the ADL rate
reported was 1.42 per person year (109 episodes over 76.81 person years). Up until the ADL
episode during which serum was collected, patients had experienced an average of 3 ADL
Fig 1. Sufficient component causemodels (SCCMs) of ADL episodes among patients with lymphatic filariasis. Each SCCM represents a sufficient
cause, which contains a minimal set of conditions that result in the outcome of interest. Each piece of the pie represents a risk factor for the outcome and is
defined as a component cause. Each pie is defined as a sufficient cause.
doi:10.1371/journal.pone.0141047.g001
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episodes during their time enrolled in the lymphedema management program. The mean time
between the ADL and convalescent serum sample was 17 days (range = 1–35). At the observed
ADL episode during which acute serum was collected, about a third of patients were treated
with an antibiotic, 70% had an enlarged lymph node, 62% presented with retrograde progres-
sion of inflammation, 75% presented with inflammation of the skin, and 81% had acute swell-
ing at the ADL site.
Two-fold antibody response
Fig 2 displays the proportion of ADL episodes with an antibody response for the filarial anti-
gens (BpG1, BpG2, BpG3, and BpG4), bacterial antigens (SEB, SPEA, SPEB, SLO, and Strep
A), and fungal antigens (Candida and Trichophyton). All responses represent a two-fold posi-
tive change of antibody level from the ADL to convalescent time point. Of the 52 paired serum
samples, 5 (9.6%) showed an antibody response to the Strep A antigen, four (7.7%) showed a
Table 1. Demographic and clinical characteristics of lymphedema patients in Léogâne, Haiti. N = 41
patients with 52 ADL episodes.
N (%)
Patient Characteristics (N = 41)
Female gender 34 (82.9)








CFA(+): ADL Time Point 1 (1.8)
CFA(+): Convalescent Time Point 1 (1.8)
Mean yearly rate of ADL episodes reported in year prior to cohort enrollment a 2.7
Mean yearly rate of ADL episodes reported during cohort period 1995–1998 1.42
Mean number of ADL episodes during study period up until serum sample b 3.3
ADL Episode Characteristics (N = 52) c
Mean number of days between ADLA and convalescent sample (range) 17 (1–35)
Treated with antibiotic during episode 14 (26.9)
Lymph node enlargement 36 (69.2)
Retrograde progression of inflammation 32 (61.5)
Inflammation of skin (redness, pain, tenderness) 39 (75.0)
Acute swelling at ADL site 42 (80.8)
a The study period of the lymphedema management effectiveness cohort = 1995–1998. This number
represents the mean yearly rate of ADL episodes reported in the year prior to their enrollment. N = 38
(missing information on 3 patients)
b The study period of the lymphedema management effectiveness cohort = 1995–1998. This number
represents the number of ADL episodes from patient enrollment in the cohort up until the observed ADL
episode during which serum was collected.
c Serum samples were collected from 52 ADL episodes among the 41 lymphedema patients
CFA: circulating filarial antigen
doi:10.1371/journal.pone.0141047.t001
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response to the BpG2 antigen, three (5.8%) showed a response to the SPEB antigen, and two
(3.9%) showed a response to the Candida antigen. Only one (1.9%) paired sample demon-
strated an antibody response to the BpG1, SEB, or SLO antigens. Our samples showed no
response at the two-fold level to the BpG3, BpG4, Pseudomonas, and SPEA antigens.
Among the bacterial antigens, Strep A had the highest proportion of two-fold response.
Among the filarial and fungal antigens, BpG2 and Candida had the highest proportions of
response respectively.
Serum antibody levels at ADL and convalescent time points
Table 2 displays the median antibody levels and standard deviations for each antigen during
the observed ADL episode and convalescent time point with the corresponding p-value,
median difference, and median percent change. All antibody levels are measured in arbitrary
units (AU). When comparing the median antibody level during the ADL episode to the median
antibody level at the convalescent time point for each antigen using a Wilcoxon signed rank
Fig 2. Proportion of ADL episodes with an antibody response for filarial, bacterial, and fungal antigens among a cohort of 52 paired serum
samples from patients enrolled in a lymphedema program in Léogâne, Haiti. Filarial antigens: BpG1, BpG2, BpG3, and BpG4. Bacterial antigens:
Pseudomonas, SEB, SPEA, SPEB, SLO, and Strep A. Fungal antigens: Candida and Trichophyton. All antibody change levels represent a 100 percent (two-
fold) increase in antibody titer from the ADL to convalescent time point.
doi:10.1371/journal.pone.0141047.g002
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test, only Pseudomonas (P-value = 0.0351) and SLO (P-value = 0.0074) showed a significant
result. The median difference between paired ADL and convalescent time points ranged from
-39.6 for BpG1 to 0.8 for SEB. The median % change between paired ADL and convalescent
time points of greatest magnitude was seen for the SLO antigen (-9.6%). The median % change
of smallest magnitude was for Trichophyton (-0.1%). SPEA had the greatest positive percent
change (2.7%). Although the median % changes are minimal, the IQRs for each antigen are
wide, indicating a great amount of variation.
Discussion
To better understand factors associated with ADL episodes among lymphedema patients in
Léogâne, Haiti, we quantified antibody levels to specific pathogens during and following an
ADL episode. We conceptualized our hypotheses and will discuss our results in the context of
sufficient component causal models (SCCM). We calculated the proportion of two-fold anti-
body responses for different pathogens hypothesized to be associated with ADL episodes. We
assumed that those pathogens showing a two-fold change from an ADL to convalescent time
point are considered a component cause of ADL episodes. Although a majority of the paired
samples did not show a two-fold increase in anti-body levels for the antigens tested, our results
showed the greatest proportion of two-fold changes in antibody levels for the Strep A antigen,
followed by BpG2, SPEB, and Candida. Amongst the bacterial antigens, the Strep A antigen for
Streptococcus A infection had the highest proportion of two-fold responses
Under our assumptions, these results support SCCM 1 (Fig 1) indicating that infection with
the bacterial pathogen Streptococcus A in combination with one or many unknown factors
(U1) could be sufficient to cause an episode of ADL. These findings are consistent with several
other studies which found a high proportion of patients undergoing ADL to be infected with
group A Streptococcus, leading to the conclusion that group A Streptococcal infection at least in
part is associated with episodes of adenolymphangitis [12,13,16]. Of the two studies which also
Table 2. Serum antibody levels stratified by sample time point as determined by ELISA tests among lymphedema patients in Léogâne, Haiti. All
values are in arbitrary units. N = 52 paired samples.
Indicator ADL Convalescent P-value* Median Absolute Difference (IQR) Median % Change (IQR)
Median SD Median SD
BpG1 1733.5 2934.2 1605.0 2629.3 0.7183 -39.6 (-209.5, 219.0) -2.0 (-21.3, 13.3)
BpG2 707.9 2424.2 781.0 1767.4 0.5404 0.3 (-78.3, 131.0) 1.2 (-20.2, 25.9)
BpG3 57.1 140.6 50.4 220.0 0.7339 -1.3 (-7.1, 14.2) -2.0 (-17.2, 20.2)
BpG4 88.8 1365.5 71.3 918.8 0.4325 -0.8 (-10.3, 10.1) -2.8 (-10.4, 7.3)
Pseudomonas 38.1 76.1 36.9 66.3 0.0351 -1.6 (-5.5, 2.5) -6.3 (-16.1, 7.0)
SEB 307.4 406.5 321.3 448.3 0.7117 -1.1 (-35.5, 33.1) -0.5 (-12.1, 10.8)
SPEA 99.4 67.4 108.8 99.4 0.3656 0.8 (-15.3, 18.6) 2.7 (-15.2, 34.3)
SPEB 28.7 23.6 25.2 23.0 0.2384 -1.0 (-8.0, 5.5) -3.2 (-30.8, 29.1)
SLO 132.6 123.8 135.8 126.8 0.0074 -12.1 (-38.5, 13.6) -9.6 (-26.8, 16.6)
Strep A 130.4 154.7 150.1 146.6 0.8493 0.3 (-25.2, 32.2) 1.7 (-26.1, 32.5)
Candida 8.6 15.5 9.0 15.6 0.6290 0.0 (-0.7, 1.5) -0.6 (-10.4, 18.6)
Trichophyton 67.3 45.9 64.7 46.3 0.9077 -0.2 (-7.0, 9.0) -0.1 (-9.1, 12.5)
* Wilcoxon- signed rank test for median difference between ADL and convalescent antibody levels
IQR = inter-quartile range
doi:10.1371/journal.pone.0141047.t002
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compared antibody levels at an ADL and convalescent time point, one found no significant rise
in the antibody response to Streptococcus A [17], while the other found a significant rise in anti-
streptolysin O (ASO) titers from an ADL to convalescent time point [16]. The latter study also
found that ADL patients had a higher mean ASO titer level than control patients, especially at
the convalescent time point.
SCCM 2 states that at minimum, filarial worm infection in combination with a set of
unknown factors U2 must be present for an ADL episode to occur. Although we saw responses
for a change in filarial antibodies, the frequency of the filarial responses was less than the fre-
quency of responses to Streptococcus A antigens, providing less evidence for the SCCM 2. Inter-
estingly, the BpG2 filarial antigens had the highest proportion of change among the filarial
antigens. Since IgG2 responses to filarial antigens are associated with carbohydrate epitopes, it
is possible that these responses reflect cross reactivity stimulated by exposure to non-filarial
antigens or even bacterial antigens. Responses to BpG4, indicating adult worm infection [28],
would be most consistent with the SCCM 2, yet among CFA (-) lymphedema patients, the
IgG4 responses are expected to be low [37,38] as seen in this cohort, thus adult worms are not
likely to be the trigger for ADL. The second most frequent filarial response at the two-fold level
was to the BpG1 antigen. Perhaps in our cohort of CFA (-) symptomatic LF patients, responses
to BpG1 may also be indicative of SCCM 2, driven by exposure to L3 larvae. The BpG1
response is thought to be associated with exposure to filarial L3 larvae [27], but these may not
necessarily result in patent infection. Combined with other unknown factors, the anti-filarial
immune response to larval exposure may be sufficient to cause ADL episodes among this
group of patients. Conversely, the anti-filarial response present in this CFA (-) cohort, though
minimal, may in part be driven by cross-reactivity with fungal and bacterial pathogens and not
due to the presence of filarial antibodies. Others have hypothesized that the antigen-negative
filarial status of some lymphedema patients may be maintained, at least in part, by recurrent
fungal and bacterial infections [22].
Our study also found that among the fungal antigens tested, the proportion of two-fold
change was highest for the Candida antigen. This evidence would support SCCM 3 (Fig 1)
where the presence of infection by a fungal pathogen such as Candida in combination with
other unknown factors would potentially be sufficient for an ADL episode to occur. Previous
studies have found evidence for the fungal pathogens as a contributing factor in the develop-
ment of ADL episodes [22,23]. Fungal infections are often found between the toes and within
deep skin folds, and can lead to inter-digital entry lesions [24]. These entry lesions can then
serve as the point of entry for bacteria leading to the ADL episodes.
Although we only observed a statistically significant difference in the median antibody level
between the ADL and convalescent samples for Pseudomonas and SLO (Table 2), the antibody
levels were highly variable as indicated by the large standard deviations and wide inter-quartile
ranges. The grouped analysis presented in Table 2 may not provide insights into the model of
ADL pathogenesis; it instead illustrates the large amount of inter-subject variability present in
this cohort. To explore this further, an analysis of variance with absolute antibody level for
each antigen as the outcome and subject as the independent variable showed R2 values ranging
from 0.83 to 0.98 (S1 Table) indicating that a large part of the variation of antibody values was
due to subject. Conversely, an ANOVA with the absolute antibody level for each antigen as the
outcome and sample time (ADL vs. convalescent) as the independent variable showed low R2
values, ranging from 0.0011 to 0.0398 (S1 Table), again indicating that much of the antibody
response variability in our cohort was due to subject. The lack of variance between the acute
and convalescent samples limits the conclusions that can be made from this study.
Among lymphedema patients who experience recurrent ADL episodes and have suffered
the chronic effects of lymphedema for many years, antibody responses may take several
Antibody Levels Associated with Acute Adenolymphangitis in Haiti
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months to wane following the initial peak after infection. Instead of oscillating antibody levels
between ADL episodes as we hypothesized, they may increase and then plateau at those higher
levels, indicating a constant heightened immune response. In a comparison of ADL patients
with healthy controls in the Dominican Republic, Vincent concluded that the mean anti-strep-
tolysin O and anti-DNAse B titer levels of the affected persons may not fully return to normal
between episodes [16].
In this context, where patients may have recurrent episodes, the threshold of antibody
change may be lower than standard levels. Therefore, we assumed that a two-fold change in
antibody level from an ADL to convalescent time point may be indicative of infection with the
pathogen of interest. We did however, explore antibody level changes at the three-fold (200%)
and four-fold (300%) levels, and found that few changed by this magnitude. We also explored
the proportion of response at lower levels, but are not confident those levels of change are
reproducible. The lack of antibody titer change from an ADL to convalescent time point at the
higher levels may be due to several factors. The study population in Léogâne, Haiti is regularly
exposed to the pathogens of interest and may already have elevated antibody titers. Therefore,
a smaller rise in antibody levels from the ADL episode to the convalescent time point may be
indicative of infection in this population.
There are several limitations in the design of this study. First, the sample size of 41 lymph-
edema patients is relatively small, limiting the external validity of our findings. Second, the 41
ADL patients who gave blood during and following an ADL episode may not have been repre-
sentative of the original cohort of 175 lymphedema patients. Although there were no differ-
ences in the gender and age distribution, the distribution of lymphedema stage, duration of
lymphedema and rate of ADL episodes reported in the year prior to study enrollment, the 41
ADL patients had a statistically significant higher rate of ADL episodes during the entire study
period (1995–1998): 1.42 per person year among patients who provided serum vs. 0.75 per per-
son year among original cohort patients (p-value<0.0001) (S2 Table). The more frequent
occurrence of ADL episodes among this subset of the original cohort may have made these
patients more willing to give blood, so that our findings may not be representative of others
that did not volunteer to give blood.
Third, all antibody values are based on arbitrary units and not on a calibrated reference
scale. Therefore, we can only explore absolute and relative differences in antibody levels
between the ADL and convalescent samples and assume certain levels of change indicate infec-
tion. Furthermore, it is possible that blood was not drawn from individuals during the most
florid period of their ADL episode. Patients were required to provide their own transportation
to and from the clinic. Those who did willingly make the trip to the clinic to give blood may
have done so after the most severe symptoms of their ADL episode had passed. If this is the
case, the antibody levels measured during the ADL episode are probably an overestimate of the
levels during the most florid time (assuming antibody levels increase over the period of inter-
est). Thus, the differences in antibody levels from ADL to convalescent time point were proba-
bly an underestimate. Also, because we chose which pathogens to test a priori, we may have
missed some component causes of ADL, which may contribute greatly to the ADL episodes in
this study population. Because most of the variance in the antibody levels was due to subject
and not due to time, our conclusions about which pathogens contributed the most to ADL epi-
sodes in this population based on arbitrary responses of change may not be as strong as find-
ings from other studies in which a control population (no ADL episode) was present.
Lastly, we only collected information from 1–3 ADL episodes among each individual in this
sample population. The lymphedema patients in the cohort have been exposed to LF for many
years and may have experienced many ADL episodes throughout their lives. We assume that
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the pathogen(s) with the greatest contribution to ADL episodes at this time point will be typical
of all ADL episodes in this population.
Through a descriptive analysis of the proportion of antibody response at a two-fold level of
change, this study provides further, yet limited evidence for infection with Streptococcus A as a
potential contributing factor of ADL episodes. However, such changes were only observed for
a small proportion of ADL episodes and the contribution of Streptococcus A to ADL episodes
in this cohort may be minimal compared to other unmeasured factors. The overall lack of
response of the paired samples may suggest that none of the pathogens tested in this study are
a major contributing factor to ADL episodes. Nonetheless, these findings are important within
the context of previous research suggesting a relationship between ADL episodes and Strepto-
coccous A and within the more recent focus on LF morbidity control in endemic areas. This
work adds to the current evidence and illustrates the importance of determining the causal role
of bacterial and fungal pathogens and immunological antifilarial response in ADL episodes.
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